Metabolic profile of NO-flurbiprofen (HCT1026) in rat brain and plasma: A LC-MS study

Life Sciences

Volumn 71, Issue 13, 2002, Pages 1487-1500

  Aldini, Giancarlo ^a   Carini, Marina ^a   Orioli, Marica ^a   Facino, Roberto Maffei ^a   Wenk, Gary L ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Brain; Flurbiprofen active metabolite; HCT1026 (nitroflurbiprofen); LC MS; Plasma

Indexed keywords

(1,1' BIPHENYL) 4 ACETIC ACID 2 FLUOROMETHYL 4 (NITROOXY)BUTYL ESTER; (1,1' BIPHENYL) 4 ACETIC ACID 2 FLUOROMETHYL 4 HYDROOXYBUTYL ESTER; ANION; CATION; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; HCT 1027; NITRATE; NITRIC OXIDE; NITRITE; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISSOCIATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CONFORMATION; DRUG DETERMINATION; DRUG MEGADOSE; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PROTON TRANSPORT; QUANTITATIVE ANALYSIS; RAT; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

ADMINISTRATION, ORAL; ANIMALS; BLOOD; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FLURBIPROFEN; MALE; MASS SPECTROMETRY; RATS; RATS, INBRED F344; REPRODUCIBILITY OF RESULTS;

ANIMALIA;

EID: 0037119059     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(02)01915-X     Document Type: Article

References (23)

1. Interleukin-6 and alpha2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices
2. Glial cytokines in Alzheimer's disease: Review and pathogenic implications
3. Pathological immuno-reactions of glial cells in Alzheimer's disease and possible sites of interference
4. Do nonsteroidal anti-inflammatory drugs decrease the risk of Alzheimer's disease? The Rotterdam Study
5. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: A current appraisal
6. Nonsteroidal anti-inflammatory drug use in Alzheimer's disease
7. Anti-inflammatory drugs and Alzheimer's disease
8. Inflammation of the brain in Alzheimer's disease: Implications for therapy
9. Inflammation and Alzheimer's disease pathogenesis
10. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat
11. Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS
12. The effects of a novel NSAID upon chronic neuroinflammation are age dependent
13. Say NO to Alzheimer's disease: The putative links between nitric oxide and dementia of the Alzheimer's type
14. NO-releasing NSAIDs are caspase inhibitors
15. Nanogram nitrite determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection
16. Nitric oxide mediates glutamate linked enhancement of cGMP levels in the cerebellum
17. NO-flurbiprofen attenuates excitotoxin-induced brain inflammation, and releases nitric oxide in the brain
18. The oxyhemoglobin reaction of nitric oxide
19. Relative role of heme nitrosylation and beta-cysteine 93 nitrosation in the transport and metabolism of nitric oxide by hemoglobin in the human circulation
20. Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: In vitro and in vivo studies in the rat by ESR spectroscopy
21. Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis
22. Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery
23. Role of tumour necrosis factor-alpha and inducible nitric oxide synthase in the prevention of nitro-flurbiprofen small intestine toxicity